282539-54-2

Upstream product

• 63-91-2 L-phenylalanine 
• 156732-12-6 (4S)-4-(N,N-dibenzylamino)-3-oxo-5-phenyl-pentanonitrile 
• 111138-83-1 N,N-dibenzyl-L-phenylalanine benzyl ester 
• 282539-49-5 ((1S,3S,4S)-4-Dibenzylamino-3-hydroxy-1-isobutyl-5-phenyl-pentyl)-carbamic acid tert-butyl ester 
• 282539-45-1 (2S,3S,5S)-5-amino-2-(dibenzylamino)-3-hydroxy-7-methyl-1-phenyloctane 
• 13335-71-2 2-(2,6-dimethylphenoxy)acetic acid 
• 282539-51-9 (2S,3S,5S)-2-amino-5-[N-tert-butyloxycarbonylamino]-3-hydroxy-7-methyl-1-phenyloctane 

Downstream Products

• 282539-52-0 N-((1S,2S,4S)-4-Amino-1-benzyl-2-hydroxy-6-methyl-heptyl)-2-(2,6-dimethyl-phenoxy)-acetamide 

Relevant academic research and scientific papers

Aspartic protease inhibitors

The present invention provides a compound of formula (I) wherein a, b, c, d, and e, are R7, OR7, SR7, NR7R8, NHCOR7, CO2R7, CN, NO2, NH2, N3, or a halogen. R7and R8are H or alkyl, R1and R2are H or alkyl, and R3is a non-aromatic substituent. Substituent A is OH, NH2, or SH. Substituents B and B1include amide and sulfonamide groups, which can be cyclic, acyclic, or amino acid derivatives. Alternatively, B and R′ together with the nitrogen to which they are bonded, and/or B′ and R2together with the nitrogen to which they are bonded, define a heterocycle. The present invention further provides a pharmaceutical composition that includes a carrier and a therapeutically effective amount of at least one compound of the present invention. The present invention further provides therapeutic methods that include administering a therapeutically effective amount of at least one compound of the present invention

Novel Lopinavir analogues incorporating non-Aromatic P-1 side chains - Synthesis and structure-activity relationships

The HIV protease inhibitor Lopinavir has a pseudosymmetric core unit incorporating benzyl groups at both P-1, P-1′ positions. A series of analogues incorporating non-aromatic side chains at the P-1 position were synthesized and the structure-activity relationships explored.